https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-04-02 / PLoS ONE 2012;7(4):e32614
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-04-02 / PLoS ONE 2012;7(4):e326142012-04-02 00:00:002019-02-15 08:46:34Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-28 / Korean J Hematol 2012 Mar;47(1):17-27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-28 / Korean J Hematol 2012 Mar;47(1):17-272012-03-28 00:00:002019-02-15 08:50:44Cellular immunotherapy using dendritic cells against multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-22 / Nat. Rev. Cancer 2012 Mar;12(4):265-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-22 / Nat. Rev. Cancer 2012 Mar;12(4):265-772012-03-22 00:00:002019-02-15 08:39:58Cancer immunotherapy via dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-20 / Cancer Immunol. Immunother. 2012 Oct;61(10):1791-804
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-20 / Cancer Immunol. Immunother. 2012 Oct;61(10):1791-8042012-03-20 00:00:002019-02-15 08:48:48Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-15 / Clin. Dev. Immunol. 2012;2012:397648
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-15 / Clin. Dev. Immunol. 2012;2012:3976482012-03-15 00:00:002019-02-15 08:50:43Immunotherapy using dendritic cells against multiple myeloma: how to improve?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-15 / J. Biomed. Biotechnol. 2012;2012:425476
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-15 / J. Biomed. Biotechnol. 2012;2012:4254762012-03-15 00:00:002019-02-15 08:39:57Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-07 / Breast Cancer Res. 2012 Mar;14(2):R39
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-07 / Breast Cancer Res. 2012 Mar;14(2):R392012-03-07 00:00:002019-02-15 08:50:03Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-01 / J Hepatobiliary Pancreat Sci 2012 Mar;19(2):171-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-01 / J Hepatobiliary Pancreat Sci 2012 Mar;19(2):171-82012-03-01 00:00:002012-03-01 00:00:00Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-01 / Expert Rev Vaccines 2012 Mar;11(3):287-302
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-01 / Expert Rev Vaccines 2012 Mar;11(3):287-3022012-03-01 00:00:002019-02-15 08:52:44Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-01 / Pancreas 2012 Mar;41(2):195-205
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-01 / Pancreas 2012 Mar;41(2):195-2052012-03-01 00:00:002019-02-15 08:52:32Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma
